Catalyst Funds Management’s AbbVie ABBV Stock Holding History

Catalyst Funds Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11.8M	Buy	47,019 +12,211	+35%	+$2.63M	0.66%	25
2026 Q1	$7.57M	Buy	+34,808	New	+$7.72M	1.28%	7
2025 Q4	–	Sell	-6,300	Closed	-$1.46M	–	331
2025 Q3	$1.46M	Buy	+6,300	New	+$1.28M	0.22%	110
2025 Q2	–	Sell	-6,300	Closed	-$1.32M	–	430
2025 Q1	$1.32M	Buy	6,300 +5,100	+425%	+$991K	0.35%	86
2024 Q4	$213K	Sell	1,200 -9,300	-89%	-$1.71M	0.05%	246
2024 Q3	$2.07M	Buy	10,500 +5,100	+94%	+$952K	0.46%	32
2024 Q2	$926K	Buy	5,400 +3,190	+144%	+$528K	0.25%	64
2024 Q1	$402K	Buy	+2,210	New	+$381K	0.11%	160

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Catalyst Funds Management's ABBV Position: Q2 2026 in Review

Catalyst Funds Management increased its AbbVie (ABBV) stake by 35% in Q2 2026, buying an estimated $2.63M and bringing the position to 47,019 shares worth $11.8M. The position accounts for 0.66% of the portfolio, ranked #25.

Catalyst Funds Management first reported a position in ABBV in Q1 2024 and has held it in 8 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Catalyst Funds Management held 47,019 shares of AbbVie worth $11.8M as of Q2 2026.
Catalyst Funds Management bought 12,211 AbbVie shares in Q2 2026, an estimated $2.63M.
AbbVie made up 0.66% of Catalyst Funds Management's portfolio in Q2 2026, its #25 holding.
Catalyst Funds Management first reported a position in AbbVie in Q1 2024 and has held it in 8 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.